LLY

735.75

-1.52%↓

JNJ

154.08

+0.56%↑

ABBV

183.18

-0.33%↓

NVO

69.37

+1.64%↑

UNH

306.43

-4.54%↓

LLY

735.75

-1.52%↓

JNJ

154.08

+0.56%↑

ABBV

183.18

-0.33%↓

NVO

69.37

+1.64%↑

UNH

306.43

-4.54%↓

LLY

735.75

-1.52%↓

JNJ

154.08

+0.56%↑

ABBV

183.18

-0.33%↓

NVO

69.37

+1.64%↑

UNH

306.43

-4.54%↓

LLY

735.75

-1.52%↓

JNJ

154.08

+0.56%↑

ABBV

183.18

-0.33%↓

NVO

69.37

+1.64%↑

UNH

306.43

-4.54%↓

LLY

735.75

-1.52%↓

JNJ

154.08

+0.56%↑

ABBV

183.18

-0.33%↓

NVO

69.37

+1.64%↑

UNH

306.43

-4.54%↓

Search

Fulgent Genetics Inc

Отворен

СекторЗдравеопазване

20.7 -2.5

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.57

Максимум

21.32

Ключови измерители

By Trading Economics

Приходи

-5.7M

-12M

Продажби

-2.8M

73M

EPS

0.04

Марж на печалбата

-16.197

Служители

1,313

EBITDA

-2M

-12M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+6.83% upside

Дивиденти

By Dow Jones

Следващи печалби

1.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

41M

613M

Предишно отваряне

23.2

Предишно затваряне

20.7

Настроения в новините

By Acuity

50%

50%

179 / 382 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Fulgent Genetics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.05.2025 г., 20:54 ч. UTC

Придобивния, сливания и поглъщания

PNC to Buy Private-Equity Agent Aqueduct Capital

20.05.2025 г., 20:50 ч. UTC

Печалби

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20.05.2025 г., 23:48 ч. UTC

Придобивния, сливания и поглъщания

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20.05.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20.05.2025 г., 23:39 ч. UTC

Пазарно говорене

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20.05.2025 г., 23:08 ч. UTC

Пазарно говорене

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20.05.2025 г., 22:45 ч. UTC

Придобивния, сливания и поглъщания

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20.05.2025 г., 22:44 ч. UTC

Топ новини

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- 2nd Update

20.05.2025 г., 22:20 ч. UTC

Топ новини

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20.05.2025 г., 22:00 ч. UTC

Печалби

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20.05.2025 г., 22:00 ч. UTC

Печалби

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20.05.2025 г., 22:00 ч. UTC

Печалби

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20.05.2025 г., 21:44 ч. UTC

Печалби

James Hardie Industries 4Q Adj EPS 36c >JHX

20.05.2025 г., 21:44 ч. UTC

Печалби

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20.05.2025 г., 21:44 ч. UTC

Печалби

James Hardie Industries 4Q EPS 10c >JHX

20.05.2025 г., 21:44 ч. UTC

Печалби

James Hardie Industries 4Q Sales $972M >JHX

20.05.2025 г., 20:52 ч. UTC

Топ новини

Elon Musk to Cut Back Political Spending -- 3rd Update

20.05.2025 г., 20:52 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.05.2025 г., 20:52 ч. UTC

Пазарно говорене

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20.05.2025 г., 20:30 ч. UTC

Придобивния, сливания и поглъщания

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20.05.2025 г., 20:28 ч. UTC

Придобивния, сливания и поглъщания

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20.05.2025 г., 20:23 ч. UTC

Придобивния, сливания и поглъщания

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20.05.2025 г., 20:22 ч. UTC

Печалби

XP 1Q Adj EPS BRL2.29 >XP

20.05.2025 г., 20:22 ч. UTC

Печалби

XP 1Q Rev BRL4.345B >XP

20.05.2025 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20.05.2025 г., 20:20 ч. UTC

Топ новини

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20.05.2025 г., 20:19 ч. UTC

Придобивния, сливания и поглъщания

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20.05.2025 г., 20:11 ч. UTC

Топ новини

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20.05.2025 г., 20:09 ч. UTC

Печалби

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

Сравнение с други в отрасъла

Ценова промяна

Fulgent Genetics Inc Прогноза

Ценова цел

By TipRanks

6.83% нагоре

12-месечна прогноза

Среден 22.67 USD  6.83%

Висок 25 USD

Нисък 20 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Fulgent Genetics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

1

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

17.32 / 19.04Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

179 / 382 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.